Anthrax - Pipeline Review, H2 2011 by GlobalMarketsDirect

VIEWS: 1 PAGES: 87

More Info
									Anthrax – Pipeline Review, H2 2011




                                 Anthrax - Pipeline Review, H2 2011
                                                                                          Reference Code: GMDHC1430IDB

                                                                                          Publication Date: October 2011




Anthrax – Pipeline Review, H2 2011                                                                               GMDHC1430IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                  Page(1)
Anthrax – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 6
      List of Figures .................................................................................................................................................................................................... 7
Introduction .............................................................................................................................................................................................................. 8
      Global Markets Direct Report Coverage ............................................................................................................................................................. 8
Anthrax Overview ..................................................................................................................................................................................................... 9
Therapeutics Development ......................................................................................................................................................................................10
      An Overview of Pipeline Products for Anthrax ...................................................................................................................................................10
Anthrax Therapeutics under Development by Companies .......................................................................................................................................12
Anthrax Therapeutics under Investigation by Universities/Institutes .........................................................................................................................14
Late Stage Products ................................................................................................................................................................................................15
      Comparative Analysis .......................................................................................................................................................................................15
Mid Clinical Stage Products .....................................................................................................................................................................................16
      Comparative Analysis .......................................................................................................................................................................................16
Early Clinical Stage Products ..................................................................................................................................................................................17
      Comparative Analysis .......................................................................................................................................................................................17
Discovery and Pre-Clinical Stage Products..............................................................................................................................................................18
      Comparative Analysis .......................................................................................................................................................................................18
Anthrax Therapeutics - Products under Development by Companies ......................................................................................................................19
Anthrax Therapeutics - Products under Investigation by Universities/Institutes ........................................................................................................21
Companies Involved in Anthrax Therapeutics Development ....................................................................................................................................22
      Aradigm Corporation .........................................................................................................................................................................................22
      AlphaRx, Inc......................................................................................................................................................................................................22
      Bavarian Nordic A/S ..........................................................................................................................................................................................23
      Emergent BioSolutions Inc. ...............................................................................................................................................................................23
      Human Genome Sciences, Inc. .........................................................................................................................................................................24
      Mitsubishi Chemical Holdings Corporation ........................................................................................................................................................24
      IR Biosciences Holdings, Inc. ............................................................................................................................................................................25
      Oragenics, Inc. ..................................................................................................................................................................................................25
      PharmAthene, Inc. ............................................................................................................................................................................................26
      Advanced Life Sciences Holdings, Inc. ..............................................................................................................................................................26
      Elusys Therapeutics, Inc. ..................................................................................................................................................................................27
      Evolva SA .........................................................................................................................................................................................................27
      Vaxin, Inc. .........................................................................................................................................................................................................27
      Exponential Biotherapies, Inc. ...........................................................................................................................................................................28
      NanoBio Corporation.........................................................................................................................................................................................28
      iBio, Inc. ............................................................................................................................................................................................................29
      NasVax Ltd. ......................................................................................................................................................................................................29
Anthrax - Therapeutics Assessment ........................................................................................................................................................................30
      Assessment by Monotherapy Products .............................................................................................................................................................30
      Assessment by Combination Products ..............................................................................................................................................................31
      Assessment by Route of Administration ............................................................................................................................................................32
      Assessment by Molecule Type ..........................................................................................................................................................................34
Drug Profiles ...........................................................................................................................................................................................................36
      Abthrax - Drug Profile........................................................................................................................................................................................36
            Product Description ....................................................................................................................................................................................36
            Mechanism of Action...................................................................................................................................................................................36


Anthrax – Pipeline Review, H2 2011                                                                                                                              GMDHC1430IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                                  Page(2)
Anthrax – Pipeline Review, H2 2011


           R&D Progress .............................................................................................................................................................................................36
     Valortim - Drug Profile .......................................................................................................................................................................................37
           Product Description ....................................................................................................................................................................................37
           Mechanism of Action...................................................................................................................................................................................37
           R&D Progress .............................................................................................................................................................................................37
     Cipro NDS - Drug Profile ...................................................................................................................................................................................38
           Product Description ....................................................................................................................................................................................38
           Mechanism of Action...................................................................................................................................................................................38
           R&D Progress .............................................................................................................................................................................................38
     Restanza - Drug Profile .....................................................................................................................................................................................39
           Product Description ....................................................................................................................................................................................39
           Mechanism of Action...................................................................................................................................................................................39
           R&D Progress .............................................................................................................................................................................................39
     ARD-1100 - Drug Profile ...................................................................................................................................................................................41
           Product Description ....................................................................................................................................................................................41
           Mechanism of Action...................................................................................................................................................................................41
           R&D Progress .............................................................................................................................................................................................41
     Viprovex - Drug Profile ......................................................................................................................................................................................42
           Product Description ....................................................................................................................................................................................42
           Mechanism of Action...................................................................................................................................................................................42
           R&D Progress .............................................................................................................................................................................................42
     MVA-BN Anthrax - Drug Profile .........................................................................................................................................................................43
           Product Description ....................................................................................................................................................................................43
           Mechanism of Action...................................................................................................................................................................................43
           R&D Progress .............................................................................................................................................................................................43
     rPA - Drug Profile ..............................................................................................................................................................................................44
           Product Description ....................................................................................................................................................................................44
           Mechanism of Action...................................................................................................................................................................................44
           R&D Progress .............................................................................................................................................................................................44
     Anthrivig - Drug Profile ......................................................................................................................................................................................45
           Product Description ....................................................................................................................................................................................45
           Mechanism of Action...................................................................................................................................................................................45
           R&D Progress .............................................................................................................................................................................................45
     Thravixa - Drug Profile ......................................................................................................................................................................................47
           Product Description ....................................................................................................................................................................................47
           Mechanism of Action...................................................................................................................................................................................47
           R&D Progress .............................................................................................................................................................................................47
     SparVax - Drug Profile ......................................................................................................................................................................................48
           Product Description ....................................................................................................................................................................................48
           Mechanism of Action...................................................................................................................................................................................48
           R&D Progress .............................................................................................................................................................................................48
     MU1140 - Drug Profile.......................................................................................................................................................................................49
           Product Description ....................................................................................................................................................................................49
           Mechanism of Action...................................................................................................................................................................................49
           R&D Progress .............................................................................................................................................................................................49
     EV-021 - Drug Profile ........................................................................................................................................................................................50
           Product Description ....................................................................................................................................................................................50
           Mechanism of Action...................................................................................................................................................................................50




Anthrax – Pipeline Review, H2 2011                                                                                                                        GMDHC1430IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                           Page(3)
Anthrax – Pipeline Review, H2 2011


          R&D Progress .............................................................................................................................................................................................50
     Drug for Anthrax - Drug Profile ..........................................................................................................................................................................51
          Product Description ....................................................................................................................................................................................51
          Mechanism of Action...................................................................................................................................................................................51
          R&D Progress .............................................................................................................................................................................................51
     Oritavancin - Drug Profile ..................................................................................................................................................................................52
          Product Description ....................................................................................................................................................................................52
          Mechanism of Action...................................................................................................................................................................................52
          R&D Progress .............................................................................................................................................................................................52
     CST-102 - Drug Profile ......................................................................................................................................................................................54
          Product Description ....................................................................................................................................................................................54
          Mechanism of Action...................................................................................................................................................................................54
          R&D Progress .............................................................................................................................................................................................54
     Anthim - Drug Profile .....................................................................................................
								
To top